Serological landscape of cytokines in cutaneous melanoma
BACKGROUND: To date, serological markers to monitor melanoma progression and response to therapy are lacking. In this context cytokines appear to be promising biomarkers of the disease. OBJECTIVE: To compare cytokine and chemokine levels in melanoma patients and in healthy controls and to assess pos...
Gespeichert in:
| Veröffentlicht in: | Cancer biomarkers : section A of Disease markers 2019-01, Vol.26 (3), p.333-342 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 342 |
|---|---|
| container_issue | 3 |
| container_start_page | 333 |
| container_title | Cancer biomarkers : section A of Disease markers |
| container_volume | 26 |
| creator | Paganelli, Alessia Garbarino, Federico Toto, Paola Martino, Giuseppe Di D’Urbano, Marika Auriemma, Matteo Giovanni, Pamela Di Panarese, Fabrizio Staniscia, Tommaso Amerio, Paolo Paganelli, Roberto |
| description | BACKGROUND:
To date, serological markers to monitor melanoma progression and response to therapy are lacking. In this context cytokines appear to be promising biomarkers of the disease.
OBJECTIVE:
To compare cytokine and chemokine levels in melanoma patients and in healthy controls and to assess possible variations according to melanoma stage.
METHODS:
Serum chemokine and cytokine levels were determined by ELISA in 34 patients diagnosed histologically of malignant melanoma. Seven healthy volunteers were used as controls.
RESULTS:
We found a subset of cytokines (CCL3, CCL4, IFN-
γ
and IL-10) to be significantly higher in melanoma patients than in control group, thus confirming the importance of the inflammation in cancer. While CCL3 increased with tumor progression, IFN-
γ
and IL-10 showed higher levels in stage I patients. Moreover, we noticed a direct correlation between CCL3 level and the presence of ulceration in the primary tumor; on the contrary, CCL4, IL-10 and IFN-
γ
were lowered down in patients with ulcerated melanoma.
CONCLUSIONS:
These results expand and confirm observations made in other studies focusing on a more limited number of molecules. This extended panel of cytokines examines the potential roles of type2 cytokines (such as IL-4) and many chemokines (mainly CCL3) as biomarkers in melanoma progression. |
| doi_str_mv | 10.3233/CBM-190370 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_AFRWT</sourceid><recordid>TN_cdi_proquest_miscellaneous_2299141841</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.3233_CBM-190370</sage_id><sourcerecordid>2299141841</sourcerecordid><originalsourceid>FETCH-LOGICAL-c347t-dd8ddea1451235ccf0d11e3ab1cc1ff35ac71b7429c0b8776cdd9a5701f803523</originalsourceid><addsrcrecordid>eNpt0E1LxDAQBuAgiruuXvwBUvCgCNVMptkkR138ghUP6jlkk3Tp2jZr0x7231vpqiCeZg4P7wwvIcdAL5EhXs1unlJQFAXdIWOQgqeSK7bb71xkKQWOI3IQ44rSDIGpfTJC4FNAJsdEvvgmlGFZWFMmpaldtGbtk5AndtOG96L2MSnqxHatqX3oYlL5XoXKHJK93JTRH23nhLzd3b7OHtL58_3j7HqeWsxEmzonnfMGMg4MubU5dQAezQKshTxHbqyAhciYsnQhhZha55ThgkIuKXKGE3I-5K6b8NH52OqqiNaX5fCPZkwpyEBm0NPTP3QVuqbuv9MMARSXgNNeXQzKNiHGxud63RSVaTYaqP7qU_d96qHPHp9sI7tF5d0P_S6wB2cDiGbpf-_9E_UJYlt6rQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2311958136</pqid></control><display><type>article</type><title>Serological landscape of cytokines in cutaneous melanoma</title><source>Sage Journals GOLD Open Access 2024</source><creator>Paganelli, Alessia ; Garbarino, Federico ; Toto, Paola ; Martino, Giuseppe Di ; D’Urbano, Marika ; Auriemma, Matteo ; Giovanni, Pamela Di ; Panarese, Fabrizio ; Staniscia, Tommaso ; Amerio, Paolo ; Paganelli, Roberto</creator><creatorcontrib>Paganelli, Alessia ; Garbarino, Federico ; Toto, Paola ; Martino, Giuseppe Di ; D’Urbano, Marika ; Auriemma, Matteo ; Giovanni, Pamela Di ; Panarese, Fabrizio ; Staniscia, Tommaso ; Amerio, Paolo ; Paganelli, Roberto</creatorcontrib><description>BACKGROUND:
To date, serological markers to monitor melanoma progression and response to therapy are lacking. In this context cytokines appear to be promising biomarkers of the disease.
OBJECTIVE:
To compare cytokine and chemokine levels in melanoma patients and in healthy controls and to assess possible variations according to melanoma stage.
METHODS:
Serum chemokine and cytokine levels were determined by ELISA in 34 patients diagnosed histologically of malignant melanoma. Seven healthy volunteers were used as controls.
RESULTS:
We found a subset of cytokines (CCL3, CCL4, IFN-
γ
and IL-10) to be significantly higher in melanoma patients than in control group, thus confirming the importance of the inflammation in cancer. While CCL3 increased with tumor progression, IFN-
γ
and IL-10 showed higher levels in stage I patients. Moreover, we noticed a direct correlation between CCL3 level and the presence of ulceration in the primary tumor; on the contrary, CCL4, IL-10 and IFN-
γ
were lowered down in patients with ulcerated melanoma.
CONCLUSIONS:
These results expand and confirm observations made in other studies focusing on a more limited number of molecules. This extended panel of cytokines examines the potential roles of type2 cytokines (such as IL-4) and many chemokines (mainly CCL3) as biomarkers in melanoma progression.</description><identifier>ISSN: 1574-0153</identifier><identifier>EISSN: 1875-8592</identifier><identifier>DOI: 10.3233/CBM-190370</identifier><identifier>PMID: 31561328</identifier><language>eng</language><publisher>London, England: SAGE Publications</publisher><subject>Adult ; Aged ; Biomarkers ; Biomarkers, Tumor - blood ; Carbon tetrachloride ; Case-Control Studies ; CCL3 protein ; CCL4 protein ; Chemokine CCL3 - blood ; Chemokine CCL4 - blood ; Chemokines ; Cytokines ; Disease Progression ; Female ; Healthy Volunteers ; Humans ; Interferon ; Interferon-gamma - blood ; Interleukin 10 ; Interleukin 4 ; Interleukin-10 - blood ; Interleukin-4 - blood ; Level (quantity) ; Male ; Melanoma ; Melanoma - blood ; Melanoma - diagnosis ; Melanoma - pathology ; Middle Aged ; Neoplasm Staging ; Skin cancer ; Skin Neoplasms - blood ; Skin Neoplasms - diagnosis ; Skin Neoplasms - pathology ; Tumors</subject><ispartof>Cancer biomarkers : section A of Disease markers, 2019-01, Vol.26 (3), p.333-342</ispartof><rights>2019 – IOS Press and the authors. All rights reserved</rights><rights>Copyright IOS Press BV 2019</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c347t-dd8ddea1451235ccf0d11e3ab1cc1ff35ac71b7429c0b8776cdd9a5701f803523</citedby><cites>FETCH-LOGICAL-c347t-dd8ddea1451235ccf0d11e3ab1cc1ff35ac71b7429c0b8776cdd9a5701f803523</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.sagepub.com/doi/pdf/10.3233/CBM-190370$$EPDF$$P50$$Gsage$$H</linktopdf><linktohtml>$$Uhttps://journals.sagepub.com/doi/10.3233/CBM-190370$$EHTML$$P50$$Gsage$$H</linktohtml><link.rule.ids>314,776,780,21945,27830,27901,27902,44921,45309</link.rule.ids><linktorsrc>$$Uhttps://journals.sagepub.com/doi/full/10.3233/CBM-190370?utm_source=summon&utm_medium=discovery-provider$$EView_record_in_SAGE_Publications$$FView_record_in_$$GSAGE_Publications</linktorsrc><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31561328$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Paganelli, Alessia</creatorcontrib><creatorcontrib>Garbarino, Federico</creatorcontrib><creatorcontrib>Toto, Paola</creatorcontrib><creatorcontrib>Martino, Giuseppe Di</creatorcontrib><creatorcontrib>D’Urbano, Marika</creatorcontrib><creatorcontrib>Auriemma, Matteo</creatorcontrib><creatorcontrib>Giovanni, Pamela Di</creatorcontrib><creatorcontrib>Panarese, Fabrizio</creatorcontrib><creatorcontrib>Staniscia, Tommaso</creatorcontrib><creatorcontrib>Amerio, Paolo</creatorcontrib><creatorcontrib>Paganelli, Roberto</creatorcontrib><title>Serological landscape of cytokines in cutaneous melanoma</title><title>Cancer biomarkers : section A of Disease markers</title><addtitle>Cancer Biomark</addtitle><description>BACKGROUND:
To date, serological markers to monitor melanoma progression and response to therapy are lacking. In this context cytokines appear to be promising biomarkers of the disease.
OBJECTIVE:
To compare cytokine and chemokine levels in melanoma patients and in healthy controls and to assess possible variations according to melanoma stage.
METHODS:
Serum chemokine and cytokine levels were determined by ELISA in 34 patients diagnosed histologically of malignant melanoma. Seven healthy volunteers were used as controls.
RESULTS:
We found a subset of cytokines (CCL3, CCL4, IFN-
γ
and IL-10) to be significantly higher in melanoma patients than in control group, thus confirming the importance of the inflammation in cancer. While CCL3 increased with tumor progression, IFN-
γ
and IL-10 showed higher levels in stage I patients. Moreover, we noticed a direct correlation between CCL3 level and the presence of ulceration in the primary tumor; on the contrary, CCL4, IL-10 and IFN-
γ
were lowered down in patients with ulcerated melanoma.
CONCLUSIONS:
These results expand and confirm observations made in other studies focusing on a more limited number of molecules. This extended panel of cytokines examines the potential roles of type2 cytokines (such as IL-4) and many chemokines (mainly CCL3) as biomarkers in melanoma progression.</description><subject>Adult</subject><subject>Aged</subject><subject>Biomarkers</subject><subject>Biomarkers, Tumor - blood</subject><subject>Carbon tetrachloride</subject><subject>Case-Control Studies</subject><subject>CCL3 protein</subject><subject>CCL4 protein</subject><subject>Chemokine CCL3 - blood</subject><subject>Chemokine CCL4 - blood</subject><subject>Chemokines</subject><subject>Cytokines</subject><subject>Disease Progression</subject><subject>Female</subject><subject>Healthy Volunteers</subject><subject>Humans</subject><subject>Interferon</subject><subject>Interferon-gamma - blood</subject><subject>Interleukin 10</subject><subject>Interleukin 4</subject><subject>Interleukin-10 - blood</subject><subject>Interleukin-4 - blood</subject><subject>Level (quantity)</subject><subject>Male</subject><subject>Melanoma</subject><subject>Melanoma - blood</subject><subject>Melanoma - diagnosis</subject><subject>Melanoma - pathology</subject><subject>Middle Aged</subject><subject>Neoplasm Staging</subject><subject>Skin cancer</subject><subject>Skin Neoplasms - blood</subject><subject>Skin Neoplasms - diagnosis</subject><subject>Skin Neoplasms - pathology</subject><subject>Tumors</subject><issn>1574-0153</issn><issn>1875-8592</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpt0E1LxDAQBuAgiruuXvwBUvCgCNVMptkkR138ghUP6jlkk3Tp2jZr0x7231vpqiCeZg4P7wwvIcdAL5EhXs1unlJQFAXdIWOQgqeSK7bb71xkKQWOI3IQ44rSDIGpfTJC4FNAJsdEvvgmlGFZWFMmpaldtGbtk5AndtOG96L2MSnqxHatqX3oYlL5XoXKHJK93JTRH23nhLzd3b7OHtL58_3j7HqeWsxEmzonnfMGMg4MubU5dQAezQKshTxHbqyAhciYsnQhhZha55ThgkIuKXKGE3I-5K6b8NH52OqqiNaX5fCPZkwpyEBm0NPTP3QVuqbuv9MMARSXgNNeXQzKNiHGxud63RSVaTYaqP7qU_d96qHPHp9sI7tF5d0P_S6wB2cDiGbpf-_9E_UJYlt6rQ</recordid><startdate>20190101</startdate><enddate>20190101</enddate><creator>Paganelli, Alessia</creator><creator>Garbarino, Federico</creator><creator>Toto, Paola</creator><creator>Martino, Giuseppe Di</creator><creator>D’Urbano, Marika</creator><creator>Auriemma, Matteo</creator><creator>Giovanni, Pamela Di</creator><creator>Panarese, Fabrizio</creator><creator>Staniscia, Tommaso</creator><creator>Amerio, Paolo</creator><creator>Paganelli, Roberto</creator><general>SAGE Publications</general><general>IOS Press BV</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TM</scope><scope>7TO</scope><scope>7U7</scope><scope>C1K</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope></search><sort><creationdate>20190101</creationdate><title>Serological landscape of cytokines in cutaneous melanoma</title><author>Paganelli, Alessia ; Garbarino, Federico ; Toto, Paola ; Martino, Giuseppe Di ; D’Urbano, Marika ; Auriemma, Matteo ; Giovanni, Pamela Di ; Panarese, Fabrizio ; Staniscia, Tommaso ; Amerio, Paolo ; Paganelli, Roberto</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c347t-dd8ddea1451235ccf0d11e3ab1cc1ff35ac71b7429c0b8776cdd9a5701f803523</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Biomarkers</topic><topic>Biomarkers, Tumor - blood</topic><topic>Carbon tetrachloride</topic><topic>Case-Control Studies</topic><topic>CCL3 protein</topic><topic>CCL4 protein</topic><topic>Chemokine CCL3 - blood</topic><topic>Chemokine CCL4 - blood</topic><topic>Chemokines</topic><topic>Cytokines</topic><topic>Disease Progression</topic><topic>Female</topic><topic>Healthy Volunteers</topic><topic>Humans</topic><topic>Interferon</topic><topic>Interferon-gamma - blood</topic><topic>Interleukin 10</topic><topic>Interleukin 4</topic><topic>Interleukin-10 - blood</topic><topic>Interleukin-4 - blood</topic><topic>Level (quantity)</topic><topic>Male</topic><topic>Melanoma</topic><topic>Melanoma - blood</topic><topic>Melanoma - diagnosis</topic><topic>Melanoma - pathology</topic><topic>Middle Aged</topic><topic>Neoplasm Staging</topic><topic>Skin cancer</topic><topic>Skin Neoplasms - blood</topic><topic>Skin Neoplasms - diagnosis</topic><topic>Skin Neoplasms - pathology</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Paganelli, Alessia</creatorcontrib><creatorcontrib>Garbarino, Federico</creatorcontrib><creatorcontrib>Toto, Paola</creatorcontrib><creatorcontrib>Martino, Giuseppe Di</creatorcontrib><creatorcontrib>D’Urbano, Marika</creatorcontrib><creatorcontrib>Auriemma, Matteo</creatorcontrib><creatorcontrib>Giovanni, Pamela Di</creatorcontrib><creatorcontrib>Panarese, Fabrizio</creatorcontrib><creatorcontrib>Staniscia, Tommaso</creatorcontrib><creatorcontrib>Amerio, Paolo</creatorcontrib><creatorcontrib>Paganelli, Roberto</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Cancer biomarkers : section A of Disease markers</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>Paganelli, Alessia</au><au>Garbarino, Federico</au><au>Toto, Paola</au><au>Martino, Giuseppe Di</au><au>D’Urbano, Marika</au><au>Auriemma, Matteo</au><au>Giovanni, Pamela Di</au><au>Panarese, Fabrizio</au><au>Staniscia, Tommaso</au><au>Amerio, Paolo</au><au>Paganelli, Roberto</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Serological landscape of cytokines in cutaneous melanoma</atitle><jtitle>Cancer biomarkers : section A of Disease markers</jtitle><addtitle>Cancer Biomark</addtitle><date>2019-01-01</date><risdate>2019</risdate><volume>26</volume><issue>3</issue><spage>333</spage><epage>342</epage><pages>333-342</pages><issn>1574-0153</issn><eissn>1875-8592</eissn><abstract>BACKGROUND:
To date, serological markers to monitor melanoma progression and response to therapy are lacking. In this context cytokines appear to be promising biomarkers of the disease.
OBJECTIVE:
To compare cytokine and chemokine levels in melanoma patients and in healthy controls and to assess possible variations according to melanoma stage.
METHODS:
Serum chemokine and cytokine levels were determined by ELISA in 34 patients diagnosed histologically of malignant melanoma. Seven healthy volunteers were used as controls.
RESULTS:
We found a subset of cytokines (CCL3, CCL4, IFN-
γ
and IL-10) to be significantly higher in melanoma patients than in control group, thus confirming the importance of the inflammation in cancer. While CCL3 increased with tumor progression, IFN-
γ
and IL-10 showed higher levels in stage I patients. Moreover, we noticed a direct correlation between CCL3 level and the presence of ulceration in the primary tumor; on the contrary, CCL4, IL-10 and IFN-
γ
were lowered down in patients with ulcerated melanoma.
CONCLUSIONS:
These results expand and confirm observations made in other studies focusing on a more limited number of molecules. This extended panel of cytokines examines the potential roles of type2 cytokines (such as IL-4) and many chemokines (mainly CCL3) as biomarkers in melanoma progression.</abstract><cop>London, England</cop><pub>SAGE Publications</pub><pmid>31561328</pmid><doi>10.3233/CBM-190370</doi><tpages>10</tpages></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | ISSN: 1574-0153 |
| ispartof | Cancer biomarkers : section A of Disease markers, 2019-01, Vol.26 (3), p.333-342 |
| issn | 1574-0153 1875-8592 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2299141841 |
| source | Sage Journals GOLD Open Access 2024 |
| subjects | Adult Aged Biomarkers Biomarkers, Tumor - blood Carbon tetrachloride Case-Control Studies CCL3 protein CCL4 protein Chemokine CCL3 - blood Chemokine CCL4 - blood Chemokines Cytokines Disease Progression Female Healthy Volunteers Humans Interferon Interferon-gamma - blood Interleukin 10 Interleukin 4 Interleukin-10 - blood Interleukin-4 - blood Level (quantity) Male Melanoma Melanoma - blood Melanoma - diagnosis Melanoma - pathology Middle Aged Neoplasm Staging Skin cancer Skin Neoplasms - blood Skin Neoplasms - diagnosis Skin Neoplasms - pathology Tumors |
| title | Serological landscape of cytokines in cutaneous melanoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T07%3A36%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_AFRWT&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Serological%20landscape%20of%20cytokines%20in%20cutaneous%20melanoma&rft.jtitle=Cancer%20biomarkers%20:%20section%20A%20of%20Disease%20markers&rft.au=Paganelli,%20Alessia&rft.date=2019-01-01&rft.volume=26&rft.issue=3&rft.spage=333&rft.epage=342&rft.pages=333-342&rft.issn=1574-0153&rft.eissn=1875-8592&rft_id=info:doi/10.3233/CBM-190370&rft_dat=%3Cproquest_AFRWT%3E2299141841%3C/proquest_AFRWT%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2311958136&rft_id=info:pmid/31561328&rft_sage_id=10.3233_CBM-190370&rfr_iscdi=true |